We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026
25 Jun 2026 - 27 Jun 2026
08 Jul 2026 - 10 Jul 2026

DSL Acquires Oxford Bio-Innovation

By HospiMedica staff writers
Posted on 12 Nov 2001
In a move that will complement its line of fertility products, Diagnostic Systems Laboratories (DSL; Webster, TX, USA) has acquired Oxford Bio-Innovation Ltd. More...
(OBI, Oxford, UK). Terms were not disclosed.

OBI makes and markets diagnostic and research products and has a clinical testing service. Its products include kits and reagents for inhibin A, inhibin B, and activin, all of which play a role in male infertility, assessment of ovarian reserve, prediction of in vitro fertilization (IVF) outcomes, and differential diagnosis of ovarian cancer. The tests are used by clinical and research laboratories worldwide.

DSL develops and manufactures products for global clinical, research, academic, and veterinary markets and currently offers more than 190 immunoassay products. These include tests for fertility and reproduction, thyroid function, growth factors, and bone and mineral metabolism.

"The acquisition of OBI positions DSL as the exclusive global provider of diagnostic tests for the measurement of inhibins and activins,” said Gopal V. Savjani, CEO of DSL.
"DSL's strength in the field of reproductive endocrinology combined with OBI's focus and experience in the area of inhibins and activins will enable us to accelerate the development of additional products and clinical applications in this field.”




Related Links:
DSL

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
Hypodermic Syringe
SurTract™ Safety Syringe
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Coredio’s CPSE is a a software-as-a-medical-device platform designed for use with consumer smartwatches and standard blood pressure cuffs in clinical and home settings under physician supervision (Photo courtesy of Coredio)

AI Platform Supports Noninvasive Remote Hemodynamic Monitoring in Heart Failure

Heart failure remains a leading cause of hospitalization in adults over 65, affecting more than 6.7 million people in the U.S. Clinicians often lose visibility into hemodynamic deterioration once patients... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.